CorFlow Therapeutics Secures 48.5M in Series B Funding to Revolutionize Microvascular Diagnosis and Treatment: Leading the Way in Cardiology Innovation

CorFlow Therapeutics is excited to announce a successful funding round, having raised an impressive $48.5 million to further its pioneering work in microvascular diagnostics and therapies.

Founded in 2016 in Baar, Switzerland, CorFlow is on a mission to enhance cardiac care by addressing the critical issue of microvascular dysfunction and obstruction, which often goes undetected during traditional percutaneous coronary interventions (PCI).

This innovative funding will accelerate the development of our groundbreaking diagnostic system designed to reveal microvascular obstruction (MVO) in real-time within the cath lab, enabling clinicians to proactively manage patient care.

Currently under ongoing clinical studies, this investigational system aims to improve the efficacy and safety of cardiac interventions, ultimately contributing to better patient outcomes.

Led by CEO Paul Mead, who has nearly two decades of medtech experience at Medtronic, and Chairman Rick Geoffrion of Cyrano Therapeutics, the company is committed to transforming the future of cardiology and beyond.

CorFlow’s strategic vision is not only to lead the market in microvascular blood flow solutions but also to uphold values centered on quality, ethical standards, and inclusivity—all while addressing significant environmental, social, and governance goals.

This latest funding round, bolstered by a combination of angel investors, venture capital, and Swiss government grants, positions CorFlow for an impactful Series B round targeted for later this year, reinforcing our relentless pursuit to meet unmet medical needs and extend the quality of human life.

We’re thrilled about the next chapter in our journey and look forward to sharing our advancements with the medical community and patients alike.